Trial of Transcranial Direct Current Stimulation (tDCS) Using Alternative Electrode Montages

The University of New South Wales1 site in 1 country29 target enrollmentNovember 2009

ConditionsMajor Depression

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Major Depression
Sponsor: The University of New South Wales
Enrollment: 29
Locations: 1
Primary Endpoint: Montgomery Asberg Depression Rating Scale for Depression (MADRS).
Status: Completed
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Among antidepressant treatments, ECT stands as the most effective in treating acute depression. However, patient concerns with the cognitive side effects of ECT have encouraged the development of new and more focal forms of brain stimulation such as transcranial Direct Current Stimulation (tDCS). Our current study of tDCS as a treatment for depression suggests that this technique has antidepressant effects and is safe, painless and well tolerated. However, not all patients may respond to this treatment in the way that it is currently administered and the concern of possible relapse in some patients who respond to tDCS has raised interest in finding alternative, possibly more optimal ways of administering tDCS. This study will investigate whether using alternative electrode montages can improve the antidepressant effects of tDCS in people suffering from depression.

Registry

clinicaltrials.gov

Start Date

November 2009

End Date

November 2015

Last Updated

9 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

The University of New South Wales

Responsible Party

Principal Investigator

Colleen Loo

Professor

The University of New South Wales

Eligibility Criteria

Inclusion Criteria

•Subject met inclusion criteria for study HREC 07305 (a sham controlled study of transcranial direct current stimulation (tDCS) as a treatment for depression).
•Subject completed study HREC
•Subject either did not reach remission at the end of trial (defined as MADRS score of ≤ 10) or suffered an early relapse (within a month of finishing the trial).

Exclusion Criteria

•Diagnosis (as defined by DSM-IV) of: any psychotic disorder (lifetime); bipolar disorder; eating disorder (current or within the past year); obsessive compulsive disorder (lifetime); post-traumatic stress disorder current or within the past year); mental retardation.
•History of drug or alcohol abuse or dependence (as per DSM-IV criteria) within the last 3 months (except nicotine and caffeine).
•Inadequate response to ECT in the current episode of depression.
•Subject is on regular benzodiazepine medication which it is not clinically appropriate to discontinue.
•Subject requires a rapid clinical response due to inanition, psychosis or high suicide risk.
•Neurological disorder or insult, e.g., recent stroke (CVA), which places subject at risk of seizure or neuronal damage with tDCS.
•Subject has metal in the cranium, skull defects, or skin lesions on scalp (cuts, abrasions, rash) at proposed electrode sites.
•Female subject who is pregnant, or of child-bearing age, sexually active and not using reliable contraception (urine test for pregnancy will be used).